… six adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. … field stimulus testing (FST), ocular instability (OCI), optical coherence tomography (OCT), and pupillary light … global trial to be conducted at sites in North America and Europe with significant expertise in genetic retinal disease. …
… Artur Cideciyan, Ph.D., professeur de recherche en ophtalmologie à l’Institut Scheie Eye de l’Université de … Vision Test ( BRVT) et le traitement précoce de la rétinopathie diabétique (ETDRS). À trois mois de traitement, … de 30 à 40 patients atteints d’ACL10 liée à une ou deux copies de la mutation p.Cys998X et pourrait être renouvelé en …
… cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced a … Vienna, Austria. The presentation titled “IPRP UPLC Method Optimization for the Separation of Short- and Longmer … and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing …
LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $7,500,000 of ordinary … proceeds from the offering to fund ongoing research and development activities and for working capital and other …
… diseases, today announced upcoming presentations at the European Cystic Fibrosis Society (ECFS) conference and the … and a poster presentation on eluforsen during the ECFS: European Cystic Fibrosis Society Conference to be held on … Eluforsen is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same … to fund its clinical trials, ongoing research and development activities and for working capital and other …
… Chief Scientific Officer Proven leader with deep worldwide ophthalmology experience, including multiple approvals … MD, who is departing ProQR. Dr. Shams brings to ProQR deep ophthalmology, scientific and research management experience, … as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global …
… PQ-110-001 Phase 1/2 trial PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) … and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients … of visual function and retinal structure through ophthalmic endpoints, such as visual acuity (BCVA), mobility …
